Composition:
Each TruGlif tablet contains 25 mg of Empagliflozin
Description:
TruGlif tablets contain empagliflozin, an orally active inhibitor of the Sodium-Glucose Co-Transporter 2 (SGLT2).
Indications:
TruGlif is indicated:
• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
Limitation of Use:
Not for the treatment of type 1 diabetes mellitus and/or diabetic ketoacidosis.
Dosage:
In individuals tolerating Truglif, the dose may be increased up to 25 mg or as directed by the physician.
DISCLAIMER
Super Health’s intention is to make sure that its consumers get information that is accurate, reviewed by an expert, and error-free. However, the information mentioned here should not be used as a replacement for the advice of a qualified physician. The information given here is for informational purposes only, and may not cover all possible precautions, side effects, contraindications, or drug interactions. Consult your doctor and discuss your queries related to any medicine or disease.
Find us on map
Reviews
There are no reviews yet